Ozempic and SSRIs (Sertraline, Escitalopram): Interaction Guide

Is there a direct interaction between Ozempic and SSRIs?

The two drugs do not share a metabolic step. Semaglutide is a GLP-1 receptor agonist given once weekly under the skin for type 2 diabetes [1]. It is not metabolized by cytochrome P450 enzymes: the peptide backbone is broken down by proteolytic cleavage and the fatty acid side chain by beta-oxidation, and about 3% of a dose is excreted unchanged in urine [1]. The Ozempic label describes a very low potential to inhibit or induce CYP enzymes [1].

SSRIs are cleared by CYP enzymes. Citalopram and escitalopram are cleared mainly by CYP3A4 and CYP2C19 [3][4]. Sertraline is itself listed as a CYP2D6 inhibitor in the Zoloft label [2]. Semaglutide is not broken down by those enzymes.

The Zoloft label's table of clinically significant interactions covers MAOIs, pimozide, other serotonergic drugs, antiplatelet and anticoagulant drugs, highly protein-bound drugs, CYP2D6 substrates, phenytoin and QTc-prolonging drugs [2]. GLP-1 receptor agonists are not on that list.

Does delayed gastric emptying change how an SSRI is absorbed?

This is the one plausible point of contact, and the Ozempic label addresses it directly. Semaglutide delays gastric emptying and so has the potential to affect absorption of oral medicines. In clinical pharmacology trials, though, it did not affect the absorption of orally administered medicines to any clinically relevant degree, and the label still advises caution when they are taken together [1].

Semaglutide interaction studies found no clinically significant effect on lisinopril, warfarin, metformin, digoxin, ethinyl estradiol, levonorgestrel, furosemide or rosuvastatin, and omeprazole did not change semaglutide levels [1][6]. Sertraline and escitalopram are not among the drugs named in these results. Separately, a study with semaglutide tablets found that levothyroxine exposure rose 33%. That result does not measure the effect of Ozempic injection [6].

Is serotonin syndrome a concern with this combination?

The Zoloft label states that serotonin syndrome can occur with an SSRI alone, and that the risk rises with other serotonergic drugs: triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, meperidine, methadone, tryptophan, buspirone, amphetamines, St John's wort and MAOIs [2]. Semaglutide acts at the GLP-1 receptor, and the Ozempic label's interactions section deals with insulin, sulfonylureas and oral medicines rather than serotonergic drugs [1].

The Zoloft label lists the signs: mental status changes such as agitation, hallucinations, delirium or coma; autonomic instability such as tachycardia, labile blood pressure, dizziness, sweating, flushing and hyperthermia; neuromuscular findings such as tremor, rigidity, myoclonus, hyperreflexia and incoordination; seizures; and gastrointestinal symptoms [2]. The label says to discontinue Zoloft and any concomitant serotonergic agents immediately and start supportive treatment if these occur [2].

What side effects overlap?

Both the Ozempic and Zoloft labels list nausea and diarrhea among reported adverse reactions [1][2], so a new symptom during semaglutide titration has more than one possible source.

Ozempic, pooled placebo-controlled trials in type 2 diabetes (placebo versus 0.5 mg versus 1 mg): nausea 6.1% versus 15.8% versus 20.3%; vomiting 2.3% versus 5% versus 9.2%; diarrhea 1.9% versus 8.5% versus 8.8%; constipation 1.5% versus 5% versus 3.1%. Any gastrointestinal reaction occurred in 15.3%, 32.7% and 36.4% respectively, and 0.4%, 3.1% and 3.8% stopped treatment for GI reasons [1].

Zoloft, pooled placebo-controlled trials in adults (sertraline versus placebo): nausea 26% versus 12%, diarrhea or loose stools 20% versus 10%, dry mouth 14% versus 9%, dyspepsia 8% versus 4%, dizziness 12% versus 8%, tremor 9% versus 2% [2].

Do the labels flag low sodium, bleeding or kidney problems?

The SSRI labels warn about hyponatremia, often from SIADH, with cases of sodium under 110 mmol/L and higher risk in older adults, people taking diuretics and people who are volume depleted; in many cases it reversed when the drug was stopped [2][3]. They also warn that SSRIs raise bleeding risk, from bruising and nosebleeds to gastrointestinal bleeding, with aspirin, NSAIDs, other antiplatelet drugs and anticoagulants adding to it [2]. A meta-analysis of 15 case-control studies (393,268 participants) plus 4 cohort studies put the odds ratio for upper GI bleeding at 1.66 (95% CI 1.44 to 1.92) with an SSRI alone and 4.25 (2.82 to 6.42) with an SSRI plus an NSAID [7]. For patients on warfarin, the Zoloft label says to monitor the INR carefully [2].

The Ozempic label reports acute kidney injury from volume depletion, mostly in people who had nausea, vomiting or diarrhea, and says to monitor renal function during dose initiation and escalation [1].

What about mood monitoring?

The SSRI boxed warning describes increased suicidal thoughts and behaviors in pediatric and young adult patients and says to monitor all antidepressant-treated patients for clinical worsening [2]. The pooled label table gives the drug-minus-placebo difference per 1,000 treated as 14 more cases under age 18, 5 more at ages 18 to 24, 1 fewer at ages 25 to 64 and 6 fewer at age 65 and over [2].

On the semaglutide side, the current Ozempic label does not include a suicidal behavior or ideation warning [1].

Which semaglutide product is this about?

Ozempic injection is approved for glycemic control in adults with type 2 diabetes, to reduce major cardiovascular events in adults with type 2 diabetes and established cardiovascular disease, and to reduce the risk of sustained eGFR decline, end-stage kidney disease and cardiovascular death in adults with type 2 diabetes and chronic kidney disease. It has no weight-loss indication [1].